Skip to content
Home/Companies/Pharma/VISUfarma
VISUfarma

VISUfarma

Pharma·UK·Exited 2026·Held 10yr
Entry
2016
Hold
10yr
Exit
2026

Who owns VISUfarma?

VISUfarma is a British Pharma company, now owned by Lupin, which acquired it in 2026 from GHO Capital.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
GHO Capital
Investor
GHO Capital
GHO Capital Fund I LP · 2015 · Buyout

Key facts

HQUK
SectorPharma
Websitewww.visufarma.com
Exit Type
Trade Sale
Buyer
Lupin
Exit Year
2026

More from GHO Capital Fund I LP

Other portfolio companies in the same fund.

BioAgilytix
Exited 2021
BiotechUS· 2018
to Cinven
Linimed-Fazmed
Active
HealthcareGermany· 2018
Caprion Biosciences
Exited 2019
BiotechCanada· 2016
to Arsenal Capital Partners
DNA Diagnostics Center
Exited 2021
HealthcareUS· 2015
to Eurofins
Quotient Clinical
Active
PharmaUK· 2015
Quotient Sciences
Exited 2019
PharmaUK· 2015
to Permira

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
AdipoPharma
AdipoPharma
Active
Capital Grand EstFrance
Advantice Health
Advantice Health
Active
TA AssociatesUS
Alcala Farma
Active
Advent InternationalSpain
Alvogen
Alvogen
Active
CVC Capital Partners
Anovo
Anovo
Active
ArdianUS

Questions

Who owns VISUfarma?

VISUfarma is now owned by Lupin, which acquired it in 2026 from GHO Capital.

When did Lupin acquire VISUfarma?

Lupin acquired VISUfarma in 2026, buying from GHO Capital.

Who did VISUfarma sell to?

GHO Capital sold VISUfarma to Lupin in 2026 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue